Electroporation therapy enters Phase II trials:
This article was originally published in Clinica
The FDA has agreed to let US company Genetronics Biomedical begin Phase II clinical trials for electroporation therapy in advanced head and neck cancer patients in whom standard treatment has failed. Electroporation allows easier and more efficient delivery of pharmaceuticals or genes by using an electric field to open the pores in human cells.
You may also be interested in...
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.
The US Medicare agency is letting ambulatory surgical centers and patient homes be reimbursed as in-patient hospitals for patient care purposes during the pandemic.
The European public assessment report for Novartis's advanced breast cancer therapy, Piqray (alpelisib), includes some interesting insights into what EU regulators are looking for in drug company clinical trials.